Provided by Tiger Trade Technology Pte. Ltd.

Esperion Therapeutics

3.18
0.0000
Volume:- -
Turnover:- -
Market Cap:816.66M
PE:-94.97
High:3.18
Open:3.18
Low:3.18
Close:3.18
52wk High:4.18
52wk Low:1.10
Shares:256.81M
Float Shares:241.66M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0335
EPS(LYR):-0.1091
ROE:97.76%
ROA:12.04%
PB:-2.65
PE(LYR):-29.14

Loading ...

Esperion to be acquired by Archimed for $3.16 per share, one CVR

TIPRANKS
·
May 01

ARCHIMED to acquire Esperion for $3.16 per share plus milestone CVR

Reuters
·
May 01

Esperion Therapeutics Inc - Shareholders to Receive $3.16 per Share Plus up to $100 Mln in Milestone Payments

THOMSON REUTERS
·
May 01

Esperion Therapeutics Inc - Transaction Is Not Subject to a Financing Condition.

THOMSON REUTERS
·
May 01

Esperion Therapeutics Inc - Deal Represents Total Equity Value of up to $1.1 Bln

THOMSON REUTERS
·
May 01

Esperion to Be Acquired by Archimed

THOMSON REUTERS
·
May 01

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM

Reuters
·
May 01

Esperion to Report First Quarter 2026 Financial Results on May 7

GlobeNewswire
·
Apr 23

Esperion Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 17

Esperion Therapeutics: Reinforced Buy Rating on Strengthened Investment Story and Conference-Driven Upside Catalysts

TIPRANKS
·
Apr 14

BRIEF-Athyrium Capital Management And Esperion Enter Into $50 Million Japan Royalty Financing To Support Strategic Acquisition Of Corstasis Therapeutics

Reuters
·
Apr 03

BRIEF-Esperion Therapeutics Enters First Amendment To Credit Agreement On April 2, 2026 - SEC Filing

Reuters
·
Apr 03

BRIEF-Esperion Therapeutics Closes Acquisition Of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise With Enbumyst™ (Bumetanide Nasal Spray)

Reuters
·
Apr 03

Esperion Therapeutics Inc - Enters First Amendment to Credit Agreement on April 2, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 03

Esperion, Athyrium Capital enter $50M royalty financing agreement

TIPRANKS
·
Apr 03

Esperion enters $50 million Japan royalty financing with Athyrium Capital Management

Reuters
·
Apr 03

Esperion Therapeutics Inc - Athyrium Funds to Receive Tiered Royalties of 12%-33% and Milestone Payments Until 2.0X Investment

THOMSON REUTERS
·
Apr 03

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

THOMSON REUTERS
·
Apr 03

Esperion Therapeutics Inc - Athyrium Funds to Buy 100% of Esperion's Royalty Interest on Otsuka's Japan Sales From Jan 1, 2026

THOMSON REUTERS
·
Apr 03

Esperion Therapeutics Inc - Financing Supports Esperion's Acquisition of Corstasis Therapeutics, Developer of Enbumyst

THOMSON REUTERS
·
Apr 03